(E)-1-(4-chlorophenyl)-3-(naphthalen-2-yl)prop-2-en-1-one

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 直链 1,3-二芳基丙烷
• 英文名称: (E)-1-(4-chlorophenyl)-3-(naphthalen-2-yl)prop-2-en-1-one
• 英文别名: (E)-1-(4-chlorophenyl)-3-naphthalen-2-ylprop-2-en-1-one
• 化学式: C₁₉H₁₃ClO
• 分子量: 292.765
• InChiKey: BDQKQQMYIJJBSH-WUXMJOGZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (E)-1-(4-chlorophenyl)-3-(naphthalen-2-yl)prop-2-en-1-one 在 1,1,2,2-tetrahydroperoxy-1,2-diphenylethane 、 potassium hydroxide 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 1.3h， 以94%的产率得到
  参考文献：
  名称：

  1,1,2,2-四氢过氧-1,2-二苯乙烷作为强力固体氧化剂对α，β-不饱和酮的无金属高效环氧化

  摘要：

  1,1,2,2-四氢过氧1,2-二苯乙烷用于各种α，β-不饱和酮的高效无金属环氧化，在室温下于弱碱性条件下进行。

  DOI：

  10.1002/jccs.201700026
• 作为产物：
  描述：

  对氯苯乙酮 、 2-萘甲醛 生成 (E)-1-(4-chlorophenyl)-3-(naphthalen-2-yl)prop-2-en-1-one
  参考文献：
  名称：

  尿素-2,2-二氢过氧丙烷作为新型氧化剂，可轻松进行α，β-不饱和酮的环氧化

  摘要：

  摘要首次使用脲-2,2-二氢过氧丙烷作为氧源，成功地将各种芳香族α，β-不饱和酮转化为相应的环氧化物。反应在室温下在弱碱性条件下以高产率和短反应时间进行。 图形概要

  DOI：

  10.1007/s13738-016-0980-1

文献信息

• [EN] ALLOSTERIC PROTEIN KINASE MODULATORS<br/>[FR] MODULATEURS DE PROTÉINE KINASE ALLOSTÉRIQUE
  申请人：UNIV SAARLAND

  公开号：WO2010043711A1

  公开（公告）日：2010-04-22

  The invention provides specific small molecule compounds that allosterically regulate the activity or modulate protein-protein interactions of AGC protein kinases and the Aurora family of protein kinases, methods for their production, pharmaceutical compositions comprising same, and their use for preparing medicaments for the treatment and prevention of diseases related to abnormal activities of AGC protein kinases or of protein kinases of the Aurora family.

  该发明提供特定的小分子化合物，这些化合物能够变构调节AGC蛋白激酶的活性或调节Aurora家族蛋白激酶的蛋白-蛋白相互作用，提供这些化合物的制备方法，包含这些化合物的药物组合物，以及它们用于制备治疗和预防与AGC蛋白激酶或Aurora家族蛋白激酶异常活动相关疾病的药物的应用。
• ALLOSTERIC PROTEIN KINASE MODULATORS
  申请人：Engel Matthias

  公开号：US20120046307A1

  公开（公告）日：2012-02-23

  The invention provides specific small molecule compounds that allosterically regulate the activity or modulate protein-protein interactions of AGC protein kinases and the Aurora family of protein kinases, methods for their production, pharmaceutical compositions comprising same, and their use for preparing medicaments for the treatment and prevention of diseases related to abnormal activities of AGC protein kinases or of protein kinases of the Aurora family.

  本发明提供了特定的小分子化合物，它们通过变构调节AGC蛋白激酶的活性或调节Aurora家族蛋白激酶的蛋白质-蛋白质相互作用，其生产方法，包含该化合物的药物组合物，以及它们用于制备治疗和预防与AGC蛋白激酶或Aurora家族蛋白激酶异常活动相关疾病的药物的应用。
• [EN] 2,3,5 TRISUBSTITUTED PYRROLE DERIVATIVES AS TOPOISOMERASE INHIBITORS AND THERAPEUTIC USES THEREOF<br/>[FR] DÉRIVÉS TRISUBSTITUÉS 2, 3, 5 DE PYRROLE EN TANT QU'INHIBITEURS DE TOPOISOMÉRASE ET LEURS UTILISATIONS THÉRAPEUTIQUES
  申请人：UNIV OF MYSORE

  公开号：WO2017029684A1

  公开（公告）日：2017-02-23

  The compounds of Formula (1) having topoisomerase inhibitory effect includes [Formula should be inserted here] wherein, R1 is selected from a group consisting of H, OR5, optionally substituted C1-C12 alkyl, haloalkyl, C2-C12alkenyl, C2-C12alkynyl, C1-C12alkyloxy, C1-C12haloalkyloxy, C2-C10 heteroalkyl, C3- C12 cycloalkyl, C3-C12cycloalkenyl, C2- C12heterocycloalkyl, C2-C2 heterocycloalkenyl, C6-C18aryl, and C1-C18heteroaryl; R2, R3 and R4 are independently selected from a group consisting of H, halogen, CN, - NO2, SH, CF3, OH, CO2H, CONH2, OCF3, optionally substituted C1-C12alkyl, optionally substituted C1-C12haloalkyl optionally substituted C2-C12alkenyl, optionally substituted C2- C12alkynyl, optionally substituted C1-C12alkyloxy, optionally substituted C1- C12haloalkyloxy, optionally substituted C2-C12heteroalkyl, optionally substituted C3- C12cycloalkyl, optionally substituted C3-C12 cycloalkenyl, optionally substituted C2-C12 heterocycloalkyl, optionally substituted C2-C12 heterocycloalkenyl, optionally substituted C6- C18aryl, and optionally substituted C1-C18heteroaryl; R5 is selected H, optionally substituted C1-C12alkyl, optionally substituted C2- C12alkenyl, optionally substituted optionally substituted C1-C12 haloalkyl, optionally substituted C3-C12cycloalkyl, optionally substituted C6- C18aryl, and optionally substituted C1- Ci18heteroaryl; or a pharmaceutically acceptable salt, N-oxide, or prodrug thereof.

  具有拓扑异构酶抑制作用的Formula（1）化合物包括[在此插入公式]其中，R1从以下组中选择：H，OR5，可选择取代的C1-C12烷基，卤代烷基，C2-C12烯基，C2-C12炔基，C1-C12烷氧基，C1-C12卤代烷氧基，C2-C10杂基烷基，C3-C12环烷基，C3-C12环烯基，C2-C12杂环烷基，C2-C2杂环烯基，C6-C18芳基和C1-C18杂芳基；R2、R3和R4分别从以下组中选择：H，卤素，CN，-NO2，SH，CF3，OH，CO2H，CONH2，O ，可选择取代的C1-C12烷基，可选择取代的C1-C12卤代烷基，可选择取代的C2-C12烯基，可选择取代的C2-C12炔基，可选择取代的C1-C12烷氧基，可选择取代的C1-C12卤代烷氧基，可选择取代的C2-C12杂基烷基，可选择取代的C3-C12环烷基，可选择取代的C3-C12环烯基，可选择取代的C2-C12杂环烷基，可选择取代的C2-C12杂环烯基，可选择取代的C6-C18芳基，可选择取代的C1-C18杂芳基；R5选择为H，可选择取代的C1-C12烷基，可选择取代的C2-C12烯基，可选择取代的可选择取代的C1-C12卤代烷基，可选择取代的C3-C12环烷基，可选择取代的C6-C18芳基，可选择取代的C1-Ci18杂芳基；或其药学上可接受的盐、N-氧化物或前药。
• Allosteric protein kinase modulators
  申请人：Universität des Saarlandes

  公开号：EP2177510A1

  公开（公告）日：2010-04-21

  The invention provides specific small molecule compounds that allosterically regulate the activity or modulate protein-protein interactions of AGC protein kinases and the Aurora family of protein kinases, methods for their production, pharmaceutical compositions comprising same, and their use for preparing medicaments for the treatment and prevention of diseases related to abnormal activities of AGC protein kinases or of protein kinases of the Aurora family.

  本发明提供了可异位调节 AGC 蛋白激酶和 Aurora 家族蛋白激酶活性或调节蛋白-蛋白相互作用的特异性小分子化合物、其生产方法、包含这些化合物的药物组合物，以及它们用于制备治疗和预防与 AGC 蛋白激酶或 Aurora 家族蛋白激酶异常活性相关疾病的药物的用途。
• Design, modification and 3D QSAR studies of novel naphthalin-containing pyrazoline derivatives with/without thiourea skeleton as anticancer agents
  作者：Wen Yang、Yang Hu、Yu-Shun Yang、Fei Zhang、Yan-Bin Zhang、Xiao-Liang Wang、Jian-Feng Tang、Wei-Qing Zhong、Hai-Liang Zhu

  DOI：10.1016/j.bmc.2013.01.013

  日期：2013.3

  Two series of novel naphthalin-containing pyrazoline derivatives C1-C14 and D1-D14 have been synthesized and evaluated for their EGFR/HER-2 inhibitory and anti-proliferation activities. Compound D14 displayed the most potent activity against EGFR and A549 cell line (IC50 = 0.05 mu M and GI(50) = 0.11 mu M), being comparable with the positive control Erlotinib (IC50 = 0.03 mu M and GI(50) = 0.03 mu M) and more potent than our previous compounds C0-A (IC50 = 5.31 mu M and GI(50) = 33.47 mu M) and C0-B (IC50 = 0.09 mu M and GI(50) = 0.34 mu M). Meanwhile, compound C14 displayed the most potent activity against HER-2 and MCF-7 cell line (IC50 = 0.88 mu M and GI(50) = 0.35 mu M), being a little less potent than Erlotinib (IC50 = 0.16 mu M and GI(50) = 0.08 mu M) but far more potent than C0-A (IC50 = 6.58 mu M and GI(50) = 27.62 mu M) and C0-B (IC50 = 2.77 mu M and GI(50) = 3.79 mu M). The docking simulation was performed to analyze the probable binding models and the QSAR models were built for reasonable design of EGFR/HER-2 inhibitors at present and in future. The structural modification of introducing naphthalin moiety reinforced the combination of our compounds and the receptor, resulting in progress of bioactivity. Moreover, the replacement of thiourea skeleton by using benzene ring resulted in the slight diversity of the two series towards specific targets. (C) 2013 Elsevier Ltd. All rights reserved.